Aura Biosciences today announced the presentation of updated clinical data from its ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the first line treatment of primary choroidal melanoma, at the American Academy of Ophthalmology (AAO) 2019 Annual Meeting, being held October 12-15, 2019 in San Francisco, CA.
Aura Biosciences today announced multiple data presentations at the upcoming American Academy of Ophthalmology (AAO) 2019 Annual Meeting being held October 12-15, 2019 in San Francisco, CA. Aura’s lead clinical asset, AU-011, will also be highlighted in presentations at related medical meetings taking place in San Francisco around AAO 2019, including the Ophthalmology Innovation Summit taking place October 10, 2019, and the American Association of Ophthalmic Oncologists and Pathologists (AAOOP) 2019 Annual Meeting taking place October 13, 2019.
We are Developing a New Class of Therapies to Target and Destroy Cancer Cells Selectively
Current treatments for cancers like ocular melanoma are highly invasive and often imprecise and toxic. We are creating a new class of therapies that can pinpoint solid tumors and metastases without harming surrounding tissue, enabling targeted treatment across a wide range of cancers.